How do different drug classes work in treating duchenne muscular dystrophy?

Overview of Duchenne Muscular Dystrophy 
Duchenne muscular dystrophy (DMD) is a severe, progressive, and ultimately fatal X‑linked recessive neuromuscular disorder characterized by the absence or near‐absence of dystrophin, a key cytoskeletal protein essential for maintaining muscle fiber integrity. The disease arises from mutations in the dystrophin gene that lead to frame-disrupting deletions, nonsense mutations, or duplications that prevent the production of the full-length dystrophin protein. Without dystrophin, muscle fibers are highly susceptible to repeated cycles of damage, leading to fiber degeneration, inflammation, fibrosis, and eventual replacement by fat and connective tissue. This cascade of pathological events not only affects skeletal muscle but also compromises cardiac and respiratory function, ultimately leading to premature death, often in the third or fourth decade of life. The genetic defect disrupts the dystrophin-glycoprotein complex (DGC), which normally provides a structural linkage between the muscle cell cytoskeleton and the extracellular matrix, and its loss induces membrane instability and mechanical stress injury during contractions.

Current Treatment Landscape 
The current treatment landscape for DMD is multifaceted. Historically, corticosteroids have been the standard of care for decades because they slow the progression of muscle weakness, improve motor function, and delay loss of ambulation even though they do not cure the disease. Alongside symptomatic management—which often includes physical therapy, ventilatory support, and cardioprotective measures—there is an active area of research focusing on therapies that target the underlying genetic defect. These include antisense oligonucleotides (AOs) designed to modulate splicing and restore the reading frame, gene therapy approaches using viral vectors to deliver modified dystrophin genes (such as mini- or micro-dystrophin) or CRISPR-based editing to repair the gene defect, and emerging pharmacological agents that target downstream effects such as inflammation, fibrosis, or impaired regeneration. Moreover, some studies have investigated combination therapies to concurrently tackle both the primary genetic abnormality and the secondary pathological processes, acknowledging the multifactorial aspects of DMD.

Drug Classes for Duchenne Muscular Dystrophy

Corticosteroids 
Corticosteroids, including prednisone, prednisolone, and deflazacort, have long been used to manage DMD. They function primarily as anti-inflammatory agents that reduce muscle damage and modulate immune-mediated injury in dystrophic muscle. Their benefit is clinically evident in improved muscle strength, delayed loss of ambulation, and in some instances prolonged respiratory and cardiac function. Corticosteroids work by binding to the glucocorticoid receptor (GR) in the cytoplasm; the receptor–ligand complex later translocates into the nucleus where it exerts transactivation and transrepression effects, ultimately downregulating pro-inflammatory genes and mitigating pathological inflammation that exacerbates muscle degeneration. Several randomized controlled trials have compared the efficacy and safety profiles of corticosteroid regimens—with deflazacort often showing a similar efficacy to prednisone with a potentially more favorable side-effect profile in terms of weight gain and bone health—underscoring their pivotal role in managing DMD symptoms.

Antisense Oligonucleotides 
Antisense oligonucleotides (AOs) represent a class of mutation-specific drugs designed to modulate pre-mRNA splicing. In DMD, many mutations lead to frameshifts that preclude the production of functional dystrophin. By binding to targeted sequences in the dystrophin pre-mRNA, AOs can induce exon skipping during mRNA processing, thereby restoring the open reading frame and allowing for the production of a truncated but partially functional dystrophin protein that is analogous to the protein expressed in Becker muscular dystrophy. Clinical trials using AOs such as eteplirsen, golodirsen, and viltolarsen have provided proof-of-concept for this strategy, although they generally require repeated administrations due to their rapid clearance and the need for high doses to achieve sufficient tissue distribution. Their development has been challenged by issues such as limited delivery to cardiac tissue and the consequent necessity to optimize chemical modifications and carrier strategies, including conjugation to cell-penetrating peptides, to enhance uptake.

Gene Therapy 
Gene therapy aims to directly address the underlying genetic defect by delivering a functional copy of the dystrophin gene or a modified, truncated version that retains critical functional domains. Since the complete dystrophin gene is too large for most viral vectors, strategies have focused on mini- or micro-dystrophin constructs that can be packaged into adeno-associated virus (AAV) vectors. These vectors have demonstrated considerable promise in preclinical studies and early-phase clinical trials by showing restoration of dystrophin expression in animal models such as the mdx mouse and the golden retriever muscular dystrophy dog. Recent advances in genome editing, including CRISPR/Cas9 technology, have also opened avenues for correcting the mutation directly in muscle tissue or stem cells. These methodologies aim for a permanent or long-lasting correction effect; however, challenges such as immune responses to the viral vectors, efficiency of transduction, and long-term safety remain to be fully addressed.

Mechanisms of Action

How Corticosteroids Work 
Corticosteroids exert a multifactorial mechanism of action in DMD. On a cellular level, these drugs diffuse through muscle cell membranes and bind to cytoplasmic glucocorticoid receptors (GRs). The activated receptor complex translocates to the nucleus, where it binds to glucocorticoid response elements (GREs), modulating gene transcription. 
• Transactivation and Transrepression: 
The GR complex activates the transcription of anti-inflammatory genes (transactivation) and suppresses the expression of pro-inflammatory cytokines by interfering with transcription factors such as NF-κB (transrepression). This dual action helps reduce chronic inflammation, which is a hallmark of DMD pathology. 
• Stabilization of Muscle Membranes: 
Although the precise molecular mechanisms are still under investigation, corticosteroids appear to confer membrane stabilizing effects that reduce the frequency and severity of contraction-induced muscle fiber necrosis. 
• Impact on Secondary Pathologies: 
By dampening inflammation, corticosteroids also slow the processes of fibrosis and fatty replacement, which further preserves muscle tissue and function over time. This overall modulation of immune responses and secondary tissue remodeling is why corticosteroids remain the only class of drugs with broadly demonstrated efficacy in DMD.

Mechanisms of Antisense Oligonucleotides 
Antisense oligonucleotides (AOs) work at the RNA level to modify pre-mRNA splicing, thereby bypassing deleterious mutations. 
• Exon Skipping: 
The principal mechanism is exon skipping. For example, in many DMD patients, mutations disrupt the reading frame. AOs are designed to hybridize to specific sequences flanking an exon, masking them from the splicing machinery. Consequently, the targeted exon is skipped during mRNA processing, restoring the reading frame even if it results in a shorter transcript. This truncated dystrophin retains some functionality, analogous to the milder Becker muscular dystrophy. 
• Chemical Modifications and Delivery: 
AOs are chemically modified (e.g., 2′-O-methyl phosphorothioate [2OMePS] or phosphorodiamidate morpholino oligomers [PMOs]) to enhance their stability and affinity, as well as reduce immunogenicity and degradation. However, these modifications also necessitate repeated dosing and often demand innovative delivery systems to reach target tissues such as skeletal and cardiac muscle effectively. 
• Dose-Response and Kinetics: 
Clinical and preclinical studies have observed that the efficacy of exon skipping is dose-dependent. Achieving clinically relevant levels of dystrophin restoration remains a challenge because optimal dosing must balance efficacy with potential toxicity or off-target effects. 
• Limitations in Cardiac Tissue: 
The heart is a major concern because AOs tend to have limited penetration in cardiac muscle compared to skeletal muscle, partly due to endosomal entrapment and less efficient cellular uptake. Researchers are exploring conjugation with cell-penetrating peptides to overcome these barriers, thus broadening the therapeutic impact of AOs in DMD.

Gene Therapy Mechanisms 
Gene therapy strategies for DMD involve several innovative approaches to restore functional dystrophin expression: 
• Gene Replacement via Viral Vectors: 
The most common method uses adeno-associated virus (AAV) vectors to deliver mini- or micro-dystrophin cassettes. Given the enormous size of the full-length dystrophin gene, truncated yet functional versions that contain the essential actin-binding and cysteine-rich domains are engineered. Once these vectors transduce muscle cells, the delivered construct is expressed, leading to the production of a dystrophin protein that, although shorter, can improve muscle membrane stability and function. 
• Genome Editing (CRISPR/Cas9): 
In recent research, genome editing has emerged as a promising alternative that directly corrects the mutation at the DNA level. CRISPR/Cas9 systems can be designed to remove mutant exons or correct point mutations in situ, thereby enabling the endogenous dystrophin gene to produce a functional protein. Animal studies have shown promising results with CRISPR-based editing in both myofibers and satellite cells, although challenges remain regarding off-target effects and immune responses. 
• Gene Correction and Exon Skipping Hybrid Strategies: 
Some approaches aim to combine the benefits of both AO-mediated exon skipping and gene therapy. For instance, sophisticated vectors can deliver components of the CRISPR system along with guide RNAs that induce exon skipping directly at the genomic level, potentially offering a one-time permanent correction compared with the repetitiveness of AO treatments. 
• Safety and Long-term Expression: 
One of the principal advantages of gene therapy is the prospect of long-term or even permanent expression of dystrophin following a single treatment; however, this must be balanced with the risks of immune responses to viral vectors or the transgene itself. Strategies to minimize these issues include using tissue-specific promoters and improved vector engineering to reduce immunogenicity.

Efficacy and Safety Considerations

Clinical Trial Results 
Clinical trial outcomes have provided crucial insights into the efficacy of these drug classes. 
• Corticosteroids: 
Numerous randomized controlled trials (RCTs) and observational studies have documented the benefits of corticosteroids in preserving muscle strength and delaying functional deterioration. For example, comparisons between deflazacort and prednisone have indicated that while both improve motor function, deflazacort may induce less weight gain and might have a somewhat different side-effect profile, leading to longer periods of ambulation in some studies. Long-term follow-ups have shown that steroid treatment can delay the onset of cardiomyopathy and respiratory failure, thus contributing to improved survival outcomes. 
• Antisense Oligonucleotides: 
In phase I/II clinical trials, AOs such as eteplirsen have demonstrated the ability to induce localized dystrophin restoration following intramuscular and systemic delivery. The production of dystrophin in treated muscles appears modest when compared to healthy levels; nevertheless, even low-level expression may correlate with slower disease progression. Other studies have indicated the need for optimized dosing regimens and enhanced delivery methods, particularly to target cardiac tissue effectively. 
• Gene Therapy: 
Early-stage clinical trials using gene replacement strategies have shown promising preliminary results with evidence of dystrophin expression after treatment with AAV-delivered micro-dystrophin constructs. However, the extent of dystrophin restoration and the sustainability of expression remain areas under active investigation. Moreover, the translation of results from animal models to human patients has underscored several challenges in achieving uniform transduction of muscle groups throughout the body. 
• Combination Approaches and Novel Endpoints: 
Recent studies underscore the potential benefits of combinatory approaches that combine genetic therapies with drugs targeting secondary pathological processes. Clinical endpoints in such studies have evolved from traditional functional measures (e.g., the six-minute walk test) to more sensitive biomarkers such as serum dystrophin levels, muscle magnetic resonance imaging (MRI), and molecular markers of inflammation, which facilitate a more refined assessment of drug efficacy.

Safety Profiles and Side Effects 
Safety remains a paramount consideration in developing and applying these therapies. 
• Corticosteroids: 
While corticosteroids are effective, their chronic use is associated with a significant adverse effect profile. Common side effects include weight gain, growth retardation, bone density loss (osteoporosis), behavioral changes, and potential adrenal suppression. Studies have shown that while deflazacort appears to have a more favorable profile with less weight gain than prednisone, it may increase the likelihood of cataract formation and also has variable effects on bone mineral density. These concerns necessitate careful monitoring and dosage adjustments in clinical practice. 
• Antisense Oligonucleotides: 
The safety profile of AOs is influenced by their chemistry and the mode of delivery. Generally, AOs have been well tolerated in early-stage trials with limited systemic toxicity. However, challenges remain, such as rapid renal clearance and potential off-target effects. In some trials, patients have experienced injection site reactions or mild systemic reactions, but these are often manageable. Concerns about long-term effects and immune responses continue to guide ongoing research, particularly as the modifications used to increase the stability of AOs may also contribute to unforeseen toxicities over extended treatment durations. 
• Gene Therapy: 
Gene therapy offers the promise of a one-time treatment; however, it is not without risks. Immune responses to AAV vectors, potential insertional mutagenesis, and off-target genome editing are areas of concern. Although many preclinical studies have mitigated these risks through advanced vector design and dosing regimens, early-phase clinical trials have reported transient immune responses and varying degrees of inflammation at the site of injection. The long-term safety of gene therapy will depend on meticulous vector engineering, immune suppression strategies during administration, and ongoing monitoring for adverse events. 
• Comparative Safety Considerations: 
When comparing these drug classes, corticosteroids have the disadvantage of cumulative side effects with long-term use, whereas the precision of AOs and gene therapy may be offset by the need for repeated dosing or potential immunogenicity, respectively. The risk–benefit balance for each therapy must be considered not only in terms of muscle strength preservation but also with regards to overall quality of life and the management of systemic complications.

Future Directions in Treatment

Emerging Therapies 
The landscape of DMD treatment is evolving steadily with several promising therapies on the horizon. 
• Next-Generation Antisense Oligonucleotides: 
Researchers are working on improving AO chemistry and delivery methods. Conjugation to cell-penetrating peptides and other innovative delivery systems are being developed to enhance uptake in both skeletal and cardiac muscle and to reduce the need for high and frequent dosing. Early preclinical data suggest that these modifications could significantly improve efficacy and broaden the applicability of AO-mediated exon skipping. 
• Advanced Gene Editing: 
The rapid advancement of CRISPR/Cas9-based genome editing technologies has opened a new frontier in DMD treatment. Ongoing research is focused on optimizing the safety and efficiency of genome editing in muscle and muscle stem cells. Approaches that combine AAV-mediated delivery with CRISPR/Cas9 editing have shown promising results in model organisms and are being refined to minimize off-target effects and immunogenicity. 
• Combined Therapeutic Strategies: 
Recognizing that DMD is a multifactorial disease, combined therapies that target both the primary genetic defect and the secondary pathological processes (e.g., fibrosis, inflammation, and muscle regeneration) are emerging as a rational next step. Trials combining gene therapy or exon skipping with drugs that modulate myostatin, improve vascularization, or enhance muscle regeneration are under exploration. 
• Novel Pharmacological Agents: 
Beyond corticosteroids, new classes of pharmacological agents that offer anti-inflammatory effects without the typical adverse effects are under trial, including dissociative steroids like vamorolone, which shows promise in preserving muscle function while reducing systemic side effects. Additionally, compounds targeting apoptosis, oxidative stress, and improved angiogenesis in dystrophic muscle are also part of the emerging therapeutic pipeline.

Research and Development Trends 
Looking forward, several trends are shaping the future of drug development for DMD: 
• Personalized Medicine: 
Given the genetic heterogeneity of DMD, personalized approaches that account for the specific mutation in each patient are likely to gain traction. This could mean tailoring antisense oligonucleotide regimens to the patient’s mutation type or applying gene-editing therapies in a mutation-specific manner. Increasing efforts in genomic diagnostics will facilitate the selection of appropriate candidates for each therapeutic strategy. 
• Enhanced Clinical Trial Design: 
Recent clinical trials have underscored the limitations of traditional endpoints in DMD, prompting a push towards more sensitive and reliable outcome measures. Innovative endpoints—such as molecular biomarkers, imaging techniques, and wearable sensor-derived functional parameters—are being incorporated into clinical trial designs to capture meaningful changes in disease progression over shorter time frames. These advanced endpoints promise to refine the assessment of drug efficacy and improve the speed at which novel therapeutics can be brought to market. 
• Multidisciplinary Collaboration: 
The complexity of DMD necessitates a broad collaborative approach among clinicians, researchers, industry experts, and patient advocacy groups. Initiatives such as clinical data consortia and regulatory science consortia are working to aggregate data from multiple sources to create robust disease progression models, guidelines, and standardized treatment protocols that can be used internationally to streamline both clinical care and research efforts. 
• Long-Term Monitoring and Registries: 
Comprehensive patient registries and long-term observational studies are increasingly recognized as critical to understanding the natural history of DMD as well as the long-term effects of novel therapies. These data sets are invaluable for optimizing trial design, understanding variability in treatment response, and assessing the real-world impact of emerging treatments.

Conclusion

In summary, the drug classes used in treating Duchenne muscular dystrophy operate through fundamentally different molecular and clinical mechanisms, each addressing a unique aspect of the disease pathology. Corticosteroids remain the most established agents for managing the secondary inflammatory and degenerative components of DMD by modulating gene expression through glucocorticoid receptor mechanisms, which helps preserve muscle function and delay disease progression despite significant long-term side effects. In contrast, antisense oligonucleotides offer a mutation-specific strategy that works at the RNA level to induce exon skipping, thereby restoring the open reading frame of the dystrophin transcript and producing a partially functional dystrophin protein. Although promising, the challenges in delivery—especially to cardiac tissue—necessitate further optimization. Gene therapy takes a more fundamental approach by attempting to replace or repair the underlying genetic defect through AAV-mediated delivery of mini- or micro-dystrophin constructs or via advanced genome editing methodologies like CRISPR/Cas9. While these strategies are on the cutting edge of medical innovation, they are still emerging and require rigorous long-term safety and efficacy evaluations in the clinical setting.

From multiple perspectives, including the molecular mechanisms of action, clinical trial outcomes, safety profiles, and emerging future directions, it is evident that each drug class has its own advantages and limitations. Corticosteroids have the advantage of broad efficacy in delaying disease milestones, but their side effects can be significant over time. Antisense oligonucleotides provide a more targeted approach and have the potential to convert the devastating DMD phenotype into a milder form akin to Becker muscular dystrophy, yet issues with delivery and dosing strategies remain challenging. Gene therapy offers hope for a one-time, long-lasting therapeutic effect but brings concerns regarding immunogenicity, vector safety, and uniform tissue distribution.

Looking forward, future directions in treatment include improving the chemical modifications and delivery vehicles for antisense oligonucleotides, refining genome editing to achieve permanent corrections with minimal off-target effects, and integrating combination therapies that address both primary genetic defects and secondary pathological cascades. There is also an increasing emphasis on personalized medicine, enhanced clinical trial design with innovative endpoints, and international collaboration to create robust patient registries and disease progression models that will ultimately facilitate more effective therapies.

In conclusion, while the current treatment landscape for DMD is characterized by both significant progress and notable challenges, the continued evolution of drug classes—from corticosteroids to antisense oligonucleotides and gene therapy—represents a comprehensive and layered approach to managing this complex disease. Each of these therapeutic strategies contributes unique benefits and faces specific hurdles, underscoring the need for multidisciplinary research, long-term clinical studies, and the careful balancing of efficacy with safety. Only through an integrated approach that combines established treatments with emerging innovative therapies will the field move closer to substantially improving the quality of life and survival for patients with Duchenne muscular dystrophy.

Discover Eureka LS: AI Agents Built for Biopharma Efficiency

Stop wasting time on biopharma busywork. Meet Eureka LS - your AI agent squad for drug discovery.

▶ See how 50+ research teams saved 300+ hours/month

From reducing screening time to simplifying Markush drafting, our AI Agents are ready to deliver immediate value. Explore Eureka LS today and unlock powerful capabilities that help you innovate with confidence.